Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Proteonomix, a biotechnology company, has announced a worldwide licensing contract for a source of primary human cells which secrete a factor capable of inhibiting tumor cell growth and causing tumor cell death.
Subscribe to our email newsletter
The anti-tumor technology consists of methods for isolation and propagation of the primary human cells, gene profiles obtained from the cells identifying candidate micro RNAs and growth factor genes, and methods for generating culture media conditioned by these cells for isolation of the inhibitory factor or factors.
Proteonomix chief technology officer Steven Byle said the recent experiments demonstrated the ability of these novel human cells and even the culture media conditioned by these cells to inhibit the proliferation of tumor cells, leading to their death.
"This technology has the potential to identify molecules that can kill tumor cells and provides insights into the potential delivery of these inhibitory factors in vivo," Byle added.
The licensing deal includes an upfront license fee, clinical and regulatory milestones based on success in developing products, in addition to royalty on sales of products resulting from the technology.